Sanofi has decided it won’t seek an approval in atopic dermatitis for amlitelimab, the OX40-ligand antibody it had hoped would be a successor to its immunological mega-blockbuster Dupixent.
July 24, 2026 06:34 AM EDT
Sanofi nixes Kymab-originated OX40L antibody in eczema
Sanofi has decided to stop working on a drug for eczema it had hoped would be a successor to its immunological mega-blockbuster Dupixent.
The French …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Sanofi halts development of troubled immune drug in eczema
Sanofi Drops Dupixent Successor Candidate After Assessing Data - Sanofi (NASDAQ:SNY)
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Q&A: Understanding the relationship between lymphoma, eczema and dupilumab
The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster.…
Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety data, ending plans for…
The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a…
The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which…
Celldex's barzolvolimab failed all efficacy measures in a Phase 2 prurigo nodularis trial, focus shifts to two Phase 3 trials for…
Sanofi is ending a Phase 3 trial of its antibody drug in a rare neurological disorder after an independent committee said the…
